Bristol-Myers Squibb Reports Data On UNITY Trial

(RTTNews) - Bristol-Myers Squibb Co. (BMY) Saturday said its 12-week regimen of daclatasvir, with asunaprevir and beclabuvir, showed sustained virologic response in 98 percent of treatment-naive and 93 percent of treatment-experienced patients with genotype 1 Hepatitis C and cirrhosis, in the Phase 3 UNITY-2 study.

In cirrhotic patients without ribavirin, the sustained virologic response was 93 percent for treatment-naive patients and 87 percent for treatment-experienced patients.

The company said it will present the study data at the Liver Meeting of the American Association for the Study of Liver Diseases.